Only in a clinical trial in patients with AML and MDS targeting CD117 with MGTA-117 a novel antibody drug conjugate with amanitin, an RNA polymerase II inhibitor, unacceptable toxicity was observed and this was most likely due to the amanitin moiety (NCT05223699). Here, KIT is linked to acute myeloid leukemia.